以下文章来源于叫小宋 别叫总 ，作者叫小宋 叫小宋 别叫总 . 一级市场从业，主要看硬科技这里讲点平时不让说的 创始人：我们最近业务不是很好。 投资人：首次见你，是在一个论坛，我到现在都能够清晰回忆起你当时的主题演讲，那段演讲 让我热血沸腾，同时也热泪盈眶。当时我就决定，一定要投你。 创始人：那个客户我们没拿下来，产品送样没通过。 投资人：为帮助对接这个客户，为了让他们同意给你测试，你知不知道我喝了多少，跑了多少 次客户？ 投资人：你知不知道我们为了你的这个课题，写了多少报告，动用了多少 l p的资源，跑了多少 所高校？ 创始人：返投落地能不能缓一缓？ 投资人：我们可以等，但是书记市长不能等， X市3 0 0万人民不能等。你们答应解决1 0 0个就 业，1 0 0个人，背后是1 0 0个家庭，这1 0 0个家庭，不能等。 创始人：业绩和上市对赌能不能缓一缓？ 投资人：我们可以等，但是产业不能等，国家不能等， 人民不能等。某国还在加严对我方的封 锁，企图将我方产业扼杀在摇篮里。 创始人：我快 6 0了，有点干不动了。 投资人：巴菲特 9 0%以上的财富都是6 0岁以后获得的。 稻盛和夫 5 2岁第二次创业，创立 ...

据悉，Altech Digital成立于2022年，通过其营运附属公司Altech Hong Kong提供两类资讯科技服务：系 统开发服务(包括开发基于互联网的系统和流动应用程序)，以及系统开发后的维修和顾问服务。数据显 示，该公司截至2025年3月31日的12个月收入为300万美元。 总部位于中国香港的IT系统开发、维护和咨询服务提供商Altech Digital周四向美国证券交易委员会 (SEC)提交了首次公开募股(IPO)申请。该公司计划以每股4美元的价格发行150万股股票，计划融资600 万美元。该公司计划在纳斯达克上市，股票代码为"ALD"。 ...

Core Viewpoint - The legal opinion letter confirms that Guangdong Provincial Architectural Science Research Institute Group Co., Ltd. has obtained all necessary approvals and authorizations for its initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market [6][8][12]. Group 1: Approval and Authorization - The company received approval and authorization from its board of directors and shareholders for the IPO on May 8, 2021, and extended the validity of these approvals on May 12, 2023, and June 2, 2023 [6][7]. - The Shenzhen Stock Exchange's Listing Review Committee has approved the company's listing application, confirming that it meets the issuance and listing conditions [7][8]. - The China Securities Regulatory Commission (CSRC) granted registration approval for the IPO, which is valid for 12 months from the date of approval [7][8]. Group 2: Company Qualifications - The company holds a valid business license issued by the Guangdong Provincial Market Supervision Administration, confirming its legal establishment and continuous operation for over three years [8][10]. - The total share capital before the IPO is 31.39 million yuan, with plans to issue no more than 10.466 million shares, ensuring that post-IPO capital will not be less than 30 million yuan [10][11]. Group 3: Substantial Conditions for Listing - The company has met the substantial conditions for listing as per the Shenzhen Stock Exchange's rules, including having a positive net profit for the years 2023 and 2024, with cumulative net profit not less than 50 million yuan [11][12]. - The company has appointed China Merchants Securities Co., Ltd. as the sponsor for the IPO, which holds the necessary qualifications to act as a sponsor [12]. Group 4: Public Commitments - The company and its controlling shareholders, directors, supervisors, and senior management have made relevant commitments regarding the IPO, ensuring compliance with legal regulations [12]. Group 5: Overall Conclusion - The legal opinion concludes that the company has obtained all necessary internal approvals, regulatory consents, and meets the legal requirements for the IPO and listing, confirming its eligibility as a publicly listed company [12].

Core Viewpoint - The company, Kewei Medical, plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its global strategy and brand recognition [1][2]. Group 1: H-Share Issuance and Listing - Kewei Medical's board and supervisory board approved the proposal for issuing H-shares and listing on the Hong Kong Stock Exchange [1]. - The company aims to accelerate its global strategy and improve its overseas business capabilities through this issuance [1]. - The timing and specifics of the issuance will be determined based on market conditions and shareholder approval within a 24-month period [1]. Group 2: Regulatory Approval and Uncertainty - The issuance and listing are subject to approval from various regulatory bodies, including the China Securities Regulatory Commission and the Hong Kong Stock Exchange [2]. - There is significant uncertainty regarding whether the issuance will receive the necessary approvals and ultimately be implemented [2]. Group 3: Previous IPO and Financials - Kewei Medical raised a total of 3.724 billion yuan from its initial public offering (IPO) in October 2021, with a net amount of 3.527 billion yuan after expenses [3]. - The company initially planned to raise 1.007 billion yuan for various projects, including a health monitoring production base and a smart medical industrial park [3]. - The total issuance costs for the IPO were 197 million yuan, with underwriting fees amounting to 174 million yuan [4].

（文章来源：第一财经） 8月9日，在2025世界机器人大会（WRC）现场，宇树科技创始人王兴兴在接受第一财经等媒体采访时 表示，他把公司上市当作一个成长过程，"我把上市当作一个类似于高考的事情，这是一个企业迈向更 成熟的管理、更成熟的运营的阶段性标志。" ...

Group 1 - The company, Puyuan Precision Electric, announced that it will hold its first extraordinary general meeting of shareholders on September 1, 2025 [1] - The agenda for the meeting includes the proposal for the company's initial public offering of H shares and listing on the Hong Kong Stock Exchange [1]

证券日报网讯 8月8日晚间，万兴科技发布公告称，公司将于2025年8月25日召开2025年第三次临时股东 会。本次股东会将审议《关于公司发行H股股票并在香港联合交易所有限公司上市的议案》等多项议 案。 （文章来源：证券日报） ...

7月29日，正品控股有限公司向港交所递交招股说明书。 招股说明书显示，正品控股计划将募集资金用于市场拓展、开设自营门店、拓展销售网络及新产品开 发。值得注意的是，正品控股营业收入高度依赖第一大客户牛奶有限公司。 毛利率逐年下滑 招股说明书显示，正品控股主要在香港从事保健及美容补充品与产品的开发、销售、营销及分销。公司 将产品生产外包给供应商（包括制造商），并主要通过万宁在香港的零售门店，分销公司自有品牌及第 三方品牌产品。 根据弗若斯特沙利文的资料，按2024年保健及美容补充品与产品的零售值计算，正品控股在香港所有本 地保健及美容补充品与产品供应商中排名第七，市场占有率约为1.6%。 | | 2023财政年度 | 2024财政年度 | 2025财政年度 | | --- | --- | --- | --- | | | 千港元 | 千港元 | 千港元 | | 收益 | 43.193 | 109.618 | 130.215 | | 銷貨成本 | (7.952) | (23.432) | (32,528) | | 毛利 | 35.241 | 86.186 | 97.687 | | 其他收入 | 863 | 208 | ...

Core Viewpoint - 正品控股有限公司 is seeking to raise funds through an IPO to expand its market presence, open self-operated stores, enhance its sales network, and develop new products, while heavily relying on its largest customer, 牛奶有限公司 [1][6]. Financial Performance - The company reported revenues of HKD 43.193 million, HKD 109.618 million, and HKD 130.215 million for the fiscal years 2023, 2024, and 2025, respectively [3]. - Net profits for the same periods were HKD 11.313 million, HKD 35.483 million, and HKD 36.257 million [3]. - Gross profit margins are projected to decline from approximately 81.6% in 2023 to 75% in 2025 [4][5]. Market Position - 正品控股 ranks seventh among local suppliers of health and beauty supplements in Hong Kong, with a market share of about 1.6% [2]. - The company primarily sells its own and third-party branded health and beauty products through retail channels, particularly through 万宁 stores [2]. Customer Dependency - The company derives a significant portion of its revenue from its top five customers, with revenues of approximately HKD 39 million, HKD 98 million, and HKD 109 million for the fiscal years 2023, 2024, and 2025, respectively, accounting for about 90.6%, 89.4%, and 83.4% of total revenue [7]. - The largest customer, 牛奶有限公司, contributed approximately HKD 39 million, HKD 84 million, and HKD 97 million to total revenues for the same periods, representing about 89.1%, 76.7%, and 74.5% of total revenue [7]. Cost Structure - The cost of goods sold is expected to increase, with costs of HKD 7.952 million, HKD 23.432 million, and HKD 32.528 million for the fiscal years 2023, 2024, and 2025, respectively [3]. - Selling and distribution expenses are projected to rise from HKD 14.912 million in 2023 to HKD 36.435 million in 2025 [3].

Group 1 - Fujian Haixi New Drug Creation Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange [1] - The joint sponsors for the listing are Huatai International and CMB International [1]